Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,138
  • Shares Outstanding, K 82,548
  • Annual Sales, $ 78,120 K
  • Annual Income, $ -153,220 K
  • EBIT $ -229 M
  • EBITDA $ -227 M
  • 60-Month Beta 1.86
  • Price/Sales 1.42
  • Price/Cash Flow N/A
  • Price/Book 0.63

Options Overview Details

View History
  • Implied Volatility 152.07% ( +12.06%)
  • Historical Volatility 102.85%
  • IV Percentile 98%
  • IV Rank 75.33%
  • IV High 189.88% on 12/16/24
  • IV Low 36.62% on 05/30/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 1,795
  • Volume Avg (30-Day) 1,124
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 42,587
  • Open Int (30-Day) 39,077

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 9
  • High Estimate 0.48
  • Low Estimate -0.86
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -30.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +2.34%
on 12/20/24
2.5350 -48.32%
on 11/22/24
-1.1000 (-45.64%)
since 11/20/24
3-Month
1.2800 +2.34%
on 12/20/24
3.8000 -65.53%
on 10/21/24
-2.4600 (-65.25%)
since 09/20/24
52-Week
1.2800 +2.34%
on 12/20/24
11.5800 -88.69%
on 02/28/24
-8.9000 (-87.17%)
since 12/20/23

Most Recent Stories

More News
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
EDIT : 1.3100 (-2.24%)
SPRO : 0.9551 (-4.30%)
Editas Medicine Advances In Vivo CRISPR-Edited Medicines, Announces Workforce Reduction and Strategic Transition

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases.Quiver AI SummaryEditas Medicine, Inc. has announced...

EDIT : 1.3100 (-2.24%)
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

EDIT : 1.3100 (-2.24%)
Editas Medicine Presents Promising Results for Reni-Cel in Severe Sickle Cell Disease at ASH Annual Meeting

Editas Medicine presents promising data on reni-cel for severe sickle cell disease at ASH, showing safety and improved hemoglobin levels.Quiver AI SummaryEditas Medicine announced that it will present...

EDIT : 1.3100 (-2.24%)
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

EDIT : 1.3100 (-2.24%)
1 Penny Stock to Grab Now for 183% Upside Potential

This biotech penny stock could more than triple, based on consensus forecasts.

VRTX : 397.27 (+0.16%)
EDIT : 1.3100 (-2.24%)
BMY : 57.33 (+1.83%)
Editas Medicine to Participate in Upcoming Investor Conferences

EDIT : 1.3100 (-2.24%)
Editas: Q3 Earnings Snapshot

Editas: Q3 Earnings Snapshot

EDIT : 1.3100 (-2.24%)
Editas Medicine Announces Third Quarter 2024 Results and Business Updates

EDIT : 1.3100 (-2.24%)
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

EDIT : 1.3100 (-2.24%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 1.4667
2nd Resistance Point 1.4233
1st Resistance Point 1.3667
Last Price 1.3100
1st Support Level 1.2667
2nd Support Level 1.2233
3rd Support Level 1.1667

See More

52-Week High 11.5800
Fibonacci 61.8% 7.6454
Fibonacci 50% 6.4300
Fibonacci 38.2% 5.2146
Last Price 1.3100
52-Week Low 1.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar